Insights

Strategic Patient Market Target the 14 million individuals living with knee osteoarthritis as a primary addressable patient pool for autologous SVF-2 therapy, emphasizing less invasive options that delay or replace joint replacement surgery.

Regulatory Momentum Leverage the ongoing pivotal trials and FDA conditional approvals to position GID BIO as a front-runner in cellular therapy for orthopedics, pursuing partnerships with clinics and hospitals planning ahead of final regulatory decisions.

Clinical Expertise Engage with the consortium of principal investigators and trial sites (New Jersey Institute of Regenerative Medicine, Tulane, Wake Forest, etc.) to create co-developed programs, expanding trial-network collaborations into commercial deployment channels.

Operational Readiness Offer turnkey, on-site SVF-2 processing programs for orthopedic centers to streamline point-of-care cellular therapy, highlighting existing trial infrastructure, operating at or near current sites with minimal onboarding friction.

Funding & Partnerships Position as a venture-ready opportunity for funds and strategic investors by aligning with moderate revenue, established funding, and potential growth trajectory, targeting biotech-focused strategic partners and healthcare systems seeking innovative osteoarthritis solutions.

Similar companies to GID BIO, Inc.

GID BIO, Inc. Tech Stack

GID BIO, Inc. uses 8 technology products and services including WordPress, Shopify, Microsoft 365, and more. Explore GID BIO, Inc.'s tech stack below.

Media & News

GID BIO, Inc.'s Email Address Formats

GID BIO, Inc. uses at least 6 email formats:
GID BIO, Inc. Email FormatsExamplePercentage
Last@thegidgroup.comDoe@thegidgroup.com
57%
F.Last@thegidgroup.comJ.Doe@thegidgroup.com
22%
FLast@thegidgroup.comJDoe@thegidgroup.com
14%
First.Last@thegidgroup.comJohn.Doe@thegidgroup.com
7%
Last@gidbio.comDoe@gidbio.com
67%
FLast@gidbio.comJDoe@gidbio.com
33%

Frequently Asked Questions

What is GID BIO, Inc.'s phone number?

Minus sign iconPlus sign icon
You can contact GID BIO, Inc.'s main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is GID BIO, Inc.'s official website and social media links?

Minus sign iconPlus sign icon
GID BIO, Inc.'s official website is gidbio.com and has social profiles on LinkedIn and Crunchbase.

How much revenue does GID BIO, Inc. generate?

Minus sign iconPlus sign icon
As of October 2026, GID BIO, Inc.'s annual revenue is estimated to be $1M - $10M.

What is GID BIO, Inc.'s SIC code and NAICS code?

Minus sign iconPlus sign icon
GID BIO, Inc.'s SIC code is 8731 - Commercial Physical and Biological Research and NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does GID BIO, Inc. have currently?

Minus sign iconPlus sign icon
As of October 2026, GID BIO, Inc. has approximately 8 employees across 2 continents, including North America and Asia. Key team members include Founder, Director: A. J. K., Executive Chairman: D. S. and Director Clinical Affairs: S. S. Explore GID BIO, Inc.'s employee directory with LeadIQ.

What industry does GID BIO, Inc. belong to?

Minus sign iconPlus sign icon
GID BIO, Inc. operates in the Biotechnology Research industry.

What technology does GID BIO, Inc. use?

Minus sign iconPlus sign icon
GID BIO, Inc.'s tech stack includes WordPress, Shopify, Microsoft 365, Google Cloud, Lenis, WP Engine, reCAPTCHA and Google Tag Manager.

What is GID BIO, Inc.'s email format?

Minus sign iconPlus sign icon
GID BIO, Inc.'s email format typically follows the pattern of Last@thegidgroup.com. Find more GID BIO, Inc. email formats with LeadIQ.

How much funding has GID BIO, Inc. raised to date?

Minus sign iconPlus sign icon
As of October 2026, GID BIO, Inc. has raised $7.6M in funding. The last funding round occurred on Sep 18, 2020 for $250K.
GID BIO, Inc. logo

GID BIO, Inc.

Biotechnology ResearchColorado, United States2-10 Employees

GID BIO, Inc. is a small biotechnology company based in Louisville, Colorado, focused on cellular therapies for knee osteoarthritis. It is developing the SVF-2 device and related therapy, which harvests, isolates and reinserts a patient's own healing cells to address osteoarthritis pain and potentially delay or avoid total knee replacement. In pivotal clinical work, the initial study reported no serious adverse events and showed meaningful improvements in pain and function, and the U.S. FDA has granted conditional approval for a second final pivotal trial.

The therapy is aimed at individuals with knee osteoarthritis and the clinicians who treat them, offering an alternative to surgery and long-term drug therapy. It addresses a substantial unmet need in a population of roughly 14 million people living with knee OA. Recent updates note ongoing pivotal-trial activities, including leadership appointments and recruitment of principal investigators across multiple trial sites.

Section iconCompany Overview

Phone number
Website
gidbio.com
SIC Code
8731 - Commercial Physical and Biological Research
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Employees
2-10

Section iconFunding & Financials

  • $7.6M

    GID BIO, Inc. has raised a total of $7.6M of funding over 4 rounds. Their latest funding round was raised on Sep 18, 2020 in the amount of $250K as a Grant.

  • $1M - $10M

    GID BIO, Inc.'s revenue is estimated to be in the range of $1M - $10M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.